Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialBeatriz Grinsztejn, Myron S. Cohen, Ian Sanne et al.|The Lancet Infectious Diseases|2014Cited by 513
Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052)Jessica M. Fogel, Susan H. Eshleman, Lei Wang et al.|The Journal of Infectious Diseases|2013Cited by 80
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 TrialSusan H. Eshleman, Myron S. Cohen, Sarah E. Hudelson et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2016Cited by 78
Adherence to Early Antiretroviral TherapySteven A. Safren, Myron S. Cohen, Kenneth H. Mayer et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2015Cited by 63
Virologic outcomes in early antiretroviral treatment: HPTN 052Susan H. Eshleman, Jessica M. Fogel, Ethan Wilson et al.|HIV Clinical Trials|2017Cited by 33